Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136309/1/pros23286.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136309/2/pros23286_am.pd
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J GeorgeDuke Cancer Institute, Durham...
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research ab...
The optimal sequence and combination of radium-223 therapy (Ra-223) for castration-resistant prostat...
BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium...
Background: Radium-233 dichloride is an alpha emitter that specifically targets bone metastases in p...
Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients ...
Radium‑223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patie...
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resist...
Radium-223; mCRPC, asymptomatic; Bone metastasesRadio-223; mCRPC, asintomático; Metástasis de huesoR...
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resist...
Introduction A number of drugs have been shown to extend life expectancy in castration-resistant pro...
Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair q...
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall surv...
Background Bone metastases frequently cause skeletal events in patients with metastatic castration-...
In this 24-month follow-up of a phase II study in patients with castration-resistant prostate cancer...
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J GeorgeDuke Cancer Institute, Durham...
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research ab...
The optimal sequence and combination of radium-223 therapy (Ra-223) for castration-resistant prostat...
BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium...
Background: Radium-233 dichloride is an alpha emitter that specifically targets bone metastases in p...
Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients ...
Radium‑223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patie...
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resist...
Radium-223; mCRPC, asymptomatic; Bone metastasesRadio-223; mCRPC, asintomático; Metástasis de huesoR...
Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resist...
Introduction A number of drugs have been shown to extend life expectancy in castration-resistant pro...
Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair q...
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall surv...
Background Bone metastases frequently cause skeletal events in patients with metastatic castration-...
In this 24-month follow-up of a phase II study in patients with castration-resistant prostate cancer...
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J GeorgeDuke Cancer Institute, Durham...
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research ab...
The optimal sequence and combination of radium-223 therapy (Ra-223) for castration-resistant prostat...
DOI
Add to ORKG